Anxiety · participants with depressive or anxiety disorders
1 finding from 1 review
Quality of life · participants with depressive or anxiety disorders
1 finding from 1 review
Social and occupational functioning · participants with depressive or anxiety disorders
1 finding from 1 review
Successful discontinuation rate · participants with long‐term antidepressants for depressive or anxiety disorders
1 finding from 1 review
Relapse · participants with long‐term antidepressants for depressive or anxiety disorders
1 finding from 1 review
Withdrawal symptoms · participants with long‐term antidepressants for depressive or anxiety disorders
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · participants with long‐term antidepressants for depressive or anxiety disorders
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Depressive symptoms · participants with long‐term antidepressants for depressive or anxiety disorders
1 finding from 1 review
Anxiety · participants with long‐term antidepressants for depressive or anxiety disorders
1 finding from 1 review
Quality of life · participants with long‐term antidepressants for depressive or anxiety disorders
1 finding from 1 review
Social and occupational functioning · participants with long‐term antidepressants for depressive or anxiety disorders
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Successful discontinuation rate · participants with depressive or anxiety disorders
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Incidence of dementia · Older people living in the community
Multi‐domain interventions showed no clear difference in incidence of dementia compared with usual care/placebo (high certainty).
1 finding from 1 review
Incidence of MCI · Older people living in the community
Multi‐domain interventions showed no clear difference in incidence of MCI compared with usual care/placebo (moderate certainty).
1 finding from 1 review
Cognitive decline · Older people living in the community
3 findings from 1 review
no estimate extracted
3 studies · 4617 participants
High
no estimate extracted
6 studies · 8697 participants
Moderate
no estimate extracted
2 studies · 1554 participants
Very low
All‐cause mortality · Older people living in the community
Multi‐domain interventions showed no clear difference in mortality compared with usual care/placebo (high certainty).
1 finding from 1 review
Mortality by day 30 · hospitalised individuals with COVID‐19 (moderate to severe disease)
Casirivimab/imdevimab showed no clear difference in mortality by day 30 compared with usual care alone (moderate certainty).
1 finding from 1 review
Mortality by day 60 · hospitalised individuals with COVID‐19 (moderate to severe disease)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Clinical progression: IMV or death (≥ 7 WHO scale) · hospitalised individuals with COVID‐19 (moderate to severe disease)
Casirivimab/imdevimab showed no clear difference in clinical progression: need for IMV or death (WHO ≥ 7) compared with usual care alone (moderate certainty).
1 finding from 1 review
Quality of life · hospitalised individuals with COVID‐19 (moderate to severe disease)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found